CY1106259T1 - Συνδυασμενη θepαπεια που πepιλαμβανει zd6474 κι ενα ταξανιο - Google Patents
Συνδυασμενη θepαπεια που πepιλαμβανει zd6474 κι ενα ταξανιοInfo
- Publication number
- CY1106259T1 CY1106259T1 CY20061101619T CY061101619T CY1106259T1 CY 1106259 T1 CY1106259 T1 CY 1106259T1 CY 20061101619 T CY20061101619 T CY 20061101619T CY 061101619 T CY061101619 T CY 061101619T CY 1106259 T1 CY1106259 T1 CY 1106259T1
- Authority
- CY
- Cyprus
- Prior art keywords
- taxane
- class
- warm
- human
- producing
- Prior art date
Links
- 238000002648 combination therapy Methods 0.000 title 1
- 229940123237 Taxane Drugs 0.000 abstract 5
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 abstract 5
- 241001465754 Metazoa Species 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 230000001772 anti-angiogenic effect Effects 0.000 abstract 2
- 238000004519 manufacturing process Methods 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 230000008728 vascular permeability Effects 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000005865 ionizing radiation Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0126879.6A GB0126879D0 (en) | 2001-11-08 | 2001-11-08 | Combination therapy |
| PCT/GB2002/005021 WO2003039551A1 (en) | 2001-11-08 | 2002-11-06 | Combination therapy comprising zd6474 and a taxane |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1106259T1 true CY1106259T1 (el) | 2011-06-08 |
Family
ID=9925430
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20061101619T CY1106259T1 (el) | 2001-11-08 | 2006-11-09 | Συνδυασμενη θepαπεια που πepιλαμβανει zd6474 κι ενα ταξανιο |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US20050043395A1 (https=) |
| EP (1) | EP1446124B1 (https=) |
| JP (1) | JP4694127B2 (https=) |
| KR (1) | KR100959607B1 (https=) |
| CN (1) | CN1298328C (https=) |
| AR (1) | AR037346A1 (https=) |
| AT (1) | ATE335488T1 (https=) |
| AU (1) | AU2002337382B2 (https=) |
| BR (1) | BR0213906A (https=) |
| CA (1) | CA2464758C (https=) |
| CY (1) | CY1106259T1 (https=) |
| DE (1) | DE60213845T2 (https=) |
| DK (1) | DK1446124T3 (https=) |
| ES (1) | ES2269769T3 (https=) |
| GB (1) | GB0126879D0 (https=) |
| IL (2) | IL161744A0 (https=) |
| MX (1) | MXPA04004355A (https=) |
| NO (1) | NO328048B1 (https=) |
| NZ (1) | NZ532525A (https=) |
| PT (1) | PT1446124E (https=) |
| WO (1) | WO2003039551A1 (https=) |
| ZA (1) | ZA200403455B (https=) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ301689B6 (cs) | 1999-11-05 | 2010-05-26 | Astrazeneca Ab | Derivát chinazolinu a farmaceutický prostredek, který ho obsahuje |
| GB0008269D0 (en) | 2000-04-05 | 2000-05-24 | Astrazeneca Ab | Combination chemotherapy |
| ES2267748T3 (es) | 2000-04-07 | 2007-03-16 | Astrazeneca Ab | Compuestos de quinazolina. |
| JP4608215B2 (ja) * | 2002-02-01 | 2011-01-12 | アストラゼネカ アクチボラグ | キナゾリン化合物 |
| TWI324597B (en) * | 2002-03-28 | 2010-05-11 | Astrazeneca Ab | Quinazoline derivatives |
| GB0218526D0 (en) * | 2002-08-09 | 2002-09-18 | Astrazeneca Ab | Combination therapy |
| GB0223380D0 (en) * | 2002-10-09 | 2002-11-13 | Astrazeneca Ab | Combination therapy |
| RU2350618C2 (ru) | 2002-11-04 | 2009-03-27 | Астразенека Аб | ПРОИЗВОДНЫЕ ХИНАЗОЛИНА В КАЧЕСТВЕ ИНГИБИТОРОВ Src ТИРОЗИНКИНАЗЫ |
| PT1592423E (pt) * | 2003-02-13 | 2011-06-16 | Astrazeneca Ab | Terapia de combinação de zd6474 com 5-fu e/ou cpt-11 |
| GB0310401D0 (en) * | 2003-05-07 | 2003-06-11 | Astrazeneca Ab | Therapeutic agent |
| EP1648465B1 (en) * | 2003-07-10 | 2010-08-25 | AstraZeneca AB | Use of the quinazoline derivative zd6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability |
| CA2545054A1 (en) * | 2003-11-14 | 2005-06-02 | Pharma Mar, S.A. | Combination therapy comprising the use of et-743 and paclitaxel for treating cancer |
| GB0406445D0 (en) * | 2004-03-23 | 2004-04-28 | Astrazeneca Ab | Combination therapy |
| GB0411378D0 (en) * | 2004-05-21 | 2004-06-23 | Astrazeneca Ab | Pharmaceutical compositions |
| JP2008504292A (ja) * | 2004-06-24 | 2008-02-14 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド | 免疫増強用の化合物 |
| KR20070072543A (ko) * | 2004-09-27 | 2007-07-04 | 아스트라제네카 아베 | Ｚｄ6474 및 이마티닙을 포함하는 병합법 |
| GB0424339D0 (en) * | 2004-11-03 | 2004-12-08 | Astrazeneca Ab | Combination therapy |
| GB0519879D0 (en) | 2005-09-30 | 2005-11-09 | Astrazeneca Ab | Chemical process |
| WO2007071958A2 (en) * | 2005-12-22 | 2007-06-28 | Astrazeneca Ab | Combination of zd6474 and pemetrexed |
| US20080045589A1 (en) * | 2006-05-26 | 2008-02-21 | Susan Kelley | Drug Combinations with Substituted Diaryl Ureas for the Treatment of Cancer |
| EP2066353B1 (en) * | 2006-09-29 | 2013-01-02 | AstraZeneca AB | Combination of zd6474 and bevacizumab for cancer therapy |
| US20080190689A1 (en) * | 2007-02-12 | 2008-08-14 | Ballard Ebbin C | Inserts for engine exhaust systems |
| EP2303276B1 (en) | 2008-05-13 | 2013-11-13 | AstraZeneca AB | Fumarate salt of 4-(3-chloro-2-fluoroanilino)-7-methoxy-6-{[1-(n-methylcarbamoylmethyl)piperidin-4-yl]oxy}quinazoline |
| WO2010061208A2 (en) * | 2008-11-03 | 2010-06-03 | Astrazeneca Ab | Therapeutic treatment 555 |
| CN106397401B (zh) * | 2016-08-30 | 2018-11-13 | 山东罗欣药业集团股份有限公司 | 一种抗癌药物的晶体化合物及其制备方法 |
| CN106478598B (zh) * | 2016-08-30 | 2018-11-13 | 山东罗欣药业集团股份有限公司 | 一种凡德他尼水合物晶体及其制备方法 |
| WO2022139304A1 (ko) * | 2020-12-22 | 2022-06-30 | 한미약품 주식회사 | Sos1 억제제로서의 신규한 퀴나졸린 유도체 화합물 및 이의 용도 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5565478A (en) * | 1994-03-14 | 1996-10-15 | The United States Of America As Represented By The Department Of Health & Human Services | Combination therapy using signal transduction inhibitors with paclitaxel and other taxane analogs |
| ES2201296T3 (es) * | 1996-04-26 | 2004-03-16 | Genaera Corporation | Escualmina en combinacion con otros farmacos anticancerigenos para el tratamiento de tumores. |
| GB9718972D0 (en) * | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| GB9727524D0 (en) * | 1997-12-31 | 1998-02-25 | Pharmacia & Upjohn Spa | Synergistic antitumor composition containing a biologically active ureido compound |
| AU768027B2 (en) * | 1999-02-24 | 2003-11-27 | Uab Research Foundation, The | Taxane derivatives for targeted therapy of cancer |
| EP1179541B1 (en) * | 1999-04-28 | 2004-06-16 | Board Of Regents, The University Of Texas System | Compositions and methods for cancer treatment by selectively inhibiting VEGF |
| CZ301689B6 (cs) * | 1999-11-05 | 2010-05-26 | Astrazeneca Ab | Derivát chinazolinu a farmaceutický prostredek, který ho obsahuje |
| TWI310684B (en) * | 2000-03-27 | 2009-06-11 | Bristol Myers Squibb Co | Synergistic pharmaceutical kits for treating cancer |
| GB0008269D0 (en) * | 2000-04-05 | 2000-05-24 | Astrazeneca Ab | Combination chemotherapy |
| GB0218526D0 (en) * | 2002-08-09 | 2002-09-18 | Astrazeneca Ab | Combination therapy |
| KR20050056190A (ko) * | 2002-08-09 | 2005-06-14 | 아스트라제네카 아베 | 암의 치료에서의 방사선 요법과 함께 혈관 내피 성장 인자수용체의 억제제인 ｚｄ6474의 병행 치료 |
| GB0223380D0 (en) * | 2002-10-09 | 2002-11-13 | Astrazeneca Ab | Combination therapy |
| PT1592423E (pt) * | 2003-02-13 | 2011-06-16 | Astrazeneca Ab | Terapia de combinação de zd6474 com 5-fu e/ou cpt-11 |
| EP1648465B1 (en) * | 2003-07-10 | 2010-08-25 | AstraZeneca AB | Use of the quinazoline derivative zd6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability |
| KR20070072543A (ko) * | 2004-09-27 | 2007-07-04 | 아스트라제네카 아베 | Ｚｄ6474 및 이마티닙을 포함하는 병합법 |
| GB0424339D0 (en) * | 2004-11-03 | 2004-12-08 | Astrazeneca Ab | Combination therapy |
| WO2007071958A2 (en) * | 2005-12-22 | 2007-06-28 | Astrazeneca Ab | Combination of zd6474 and pemetrexed |
| EP2066353B1 (en) * | 2006-09-29 | 2013-01-02 | AstraZeneca AB | Combination of zd6474 and bevacizumab for cancer therapy |
-
2001
- 2001-11-08 GB GBGB0126879.6A patent/GB0126879D0/en not_active Ceased
-
2002
- 2002-11-06 MX MXPA04004355A patent/MXPA04004355A/es active IP Right Grant
- 2002-11-06 CN CNB028267958A patent/CN1298328C/zh not_active Expired - Fee Related
- 2002-11-06 ES ES02772624T patent/ES2269769T3/es not_active Expired - Lifetime
- 2002-11-06 EP EP02772624A patent/EP1446124B1/en not_active Expired - Lifetime
- 2002-11-06 DE DE60213845T patent/DE60213845T2/de not_active Expired - Lifetime
- 2002-11-06 US US10/494,704 patent/US20050043395A1/en not_active Abandoned
- 2002-11-06 KR KR1020047007020A patent/KR100959607B1/ko not_active Expired - Fee Related
- 2002-11-06 IL IL16174402A patent/IL161744A0/xx unknown
- 2002-11-06 AT AT02772624T patent/ATE335488T1/de active
- 2002-11-06 CA CA2464758A patent/CA2464758C/en not_active Expired - Fee Related
- 2002-11-06 NZ NZ532525A patent/NZ532525A/en not_active IP Right Cessation
- 2002-11-06 JP JP2003541842A patent/JP4694127B2/ja not_active Expired - Fee Related
- 2002-11-06 WO PCT/GB2002/005021 patent/WO2003039551A1/en not_active Ceased
- 2002-11-06 AU AU2002337382A patent/AU2002337382B2/en not_active Ceased
- 2002-11-06 DK DK02772624T patent/DK1446124T3/da active
- 2002-11-06 BR BR0213906-5A patent/BR0213906A/pt not_active IP Right Cessation
- 2002-11-06 PT PT02772624T patent/PT1446124E/pt unknown
- 2002-11-08 AR ARP020104292A patent/AR037346A1/es not_active Application Discontinuation
-
2004
- 2004-05-03 IL IL161744A patent/IL161744A/en not_active IP Right Cessation
- 2004-05-06 ZA ZA200403455A patent/ZA200403455B/en unknown
- 2004-06-07 NO NO20042365A patent/NO328048B1/no not_active IP Right Cessation
-
2006
- 2006-11-09 CY CY20061101619T patent/CY1106259T1/el unknown
-
2011
- 2011-11-07 US US13/290,730 patent/US20120252827A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ES2269769T3 (es) | 2007-04-01 |
| PT1446124E (pt) | 2006-12-29 |
| JP2005511597A (ja) | 2005-04-28 |
| CN1612738A (zh) | 2005-05-04 |
| WO2003039551A1 (en) | 2003-05-15 |
| EP1446124A1 (en) | 2004-08-18 |
| HK1068546A1 (en) | 2005-04-29 |
| US20050043395A1 (en) | 2005-02-24 |
| NO20042365L (no) | 2004-06-07 |
| ZA200403455B (en) | 2005-08-29 |
| CA2464758C (en) | 2010-09-28 |
| AU2002337382B2 (en) | 2008-06-12 |
| DE60213845T2 (de) | 2007-03-29 |
| IL161744A0 (en) | 2005-11-20 |
| MXPA04004355A (es) | 2004-08-11 |
| KR20050043779A (ko) | 2005-05-11 |
| KR100959607B1 (ko) | 2010-05-27 |
| CN1298328C (zh) | 2007-02-07 |
| JP4694127B2 (ja) | 2011-06-08 |
| IL161744A (en) | 2012-01-31 |
| DK1446124T3 (da) | 2006-11-13 |
| DE60213845D1 (de) | 2006-09-21 |
| EP1446124B1 (en) | 2006-08-09 |
| GB0126879D0 (en) | 2002-01-02 |
| ATE335488T1 (de) | 2006-09-15 |
| AR037346A1 (es) | 2004-11-03 |
| CA2464758A1 (en) | 2003-05-15 |
| BR0213906A (pt) | 2004-08-31 |
| US20120252827A1 (en) | 2012-10-04 |
| NZ532525A (en) | 2006-11-30 |
| NO328048B1 (no) | 2009-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1106259T1 (el) | Συνδυασμενη θepαπεια που πepιλαμβανει zd6474 κι ενα ταξανιο | |
| CY1106601T1 (el) | Χρηση του παραγωγου κουιναζολινης zd6474 συνδυασμενου με γκεμσιταμπινη και προαιρετικα με ιοντιζουσα ακτινοβολια στη θεραπεια του καρκινου | |
| NO20071426L (no) | Kreft kombinasjonsbehandling omfattende AZD2171 og Imatinib | |
| CY1111547T1 (el) | Συνδυασμος zd6474 και πεμετρεξεδης | |
| CY1111482T1 (el) | Συνδυασμος azd2171 και πεμετρεξεδης | |
| MX2007003505A (es) | Combinacion que comprende zd6474 e imatinib. | |
| PT1653964E (pt) | Terapia de combinação para o cancro compreendendo azd2171 e zd1839 | |
| ATE385798T1 (de) | Pharmazeutische zubereitungen enthaltend azd 2171 und zd 6126 und verwendungen | |
| NO20064755L (no) | Kombinasjonsterapi | |
| NO20064754L (no) | Kombinasjonsterapi | |
| NO20064753L (no) | Kombinasjonsterapi | |
| ATE339209T1 (de) | Kombinationstherapie mit gemzitabin und zd6126 |